{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Kintara Therapeutics, Inc.
Is Kintara Therapeutics, Inc. technically bullish or bearish?
As of May 12, 2025, the technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and daily moving averages, despite a mildly bullish monthly KST, with overall indicators suggesting weakness and underperformance against the S&P 500.
Who are in the management team of Kintara Therapeutics, Inc.?
As of March 2022, Kintara Therapeutics, Inc.'s management team includes Mr. Robert Hoffman (Independent Chairman), Mr. Saiid Zarrabian (President and CEO), and Directors Mr. John Liatos, Mr. Keith Murphy, and Mr. Robert Toth. They oversee the company's strategic direction and operations.
What does Kintara Therapeutics, Inc. do?
Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on cancer treatment, with a market cap of $103.60 million and a recent net profit loss of $7 million. The company has no dividend yield and significant negative return on equity.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
